Eli Lilly Boston Consulting Group Matrix
See the Bigger Picture
Eli Lilly’s BCG Matrix preview shows which drugs are driving growth and which might be holding you back — a quick lens on Stars, Cash Cows, Question Marks, and Dogs. Want the full picture? Purchase the complete BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word + Excel files to guide investment and portfolio decisions. Get instant clarity and skip the guesswork.
Stars
Mounjaro (tirzepatide) — T2D
Mounjaro (tirzepatide) is a BCG Star: runaway 2024 demand and a fat order book fuel massive share in injectable T2D/weight markets. Clinical and real-world data show up to 1.8–2.0% HbA1c reduction and SURMOUNT-1 weight loss to 22.5%, underpinning sustained uptake. Continued value depends on aggressive supply build-out and global rollout muscle to avoid shortages. Keep feeding it and it prints the next decade.
Zepbound (tirzepatide) — Obesity
Zepbound (tirzepatide) — approved by the FDA for chronic weight management on November 8, 2023 — has driven explosive category-defining demand and cultural momentum, quickly taking high share in a still-accelerating obesity market. Marketing, payer access negotiations, and rapid manufacturing scale-up require heavy ongoing investment to sustain growth and convert market lead into a long-term annuity.
Verzenio (abemaciclib) — HR+/HER2− breast cancer
Verzenio (abemaciclib) has strong guideline presence after FDA adjuvant approval in 2021 based on monarchE, and is endorsed in major guidelines such as NCCN and ESMO for HR+/HER2− high‑risk disease.
It is gaining share within the still‑growing CDK4/6 class versus competitors but requires continued confirmatory evidence and geographic label expansions to defend market position.
Ongoing investment in trials, real‑world evidence generation and global rollout is required to keep uptake and revenue trajectory rising.
Jardiance (empagliflozin) — cardio-renal-metabolic (alliance)
Category leader with broad labels and durable physician habit; alliance Jardiance recorded roughly $10 billion global sales in 2024 and continues double-digit volume growth across HF, CKD and T2D. Market still growing: SGLT2 class expected mid-to-high single-digit CAGR, driven by expanding HF/CKD indications and rising prescriptions. Co-promote economics improve with scale; keep flywheel spinning via outcomes readouts and access wins.
- leader
- ~$10B 2024 sales
- expanding HF/CKD/T2D labels
- co-promote economics scale
- focus on outcomes & access
Taltz (ixekizumab) — Immunology
Taltz (ixekizumab) remains a Star for Eli Lilly with leading share in psoriasis and axial spondyloarthritis and healthy new-start volumes in 2024; IL-17 biologics continue double-digit market growth as biologic penetration rises. Competitive landscape is intense but patient retention is high once responders achieve remission; focus on speed of onset and superior skin clearance sustains differentiation.
- 2024: strong new-start momentum, double-digit class growth
- High market share across psoriasis and axSpA
- Sticky adherence once patients respond
- Key differentiator: rapid onset and skin clearance
GLP-1 leaders fuel demand; oncology/IL-17 champs expand; SGLT2 hits $10B
Mounjaro and Zepbound are Stars: category-defining demand and rapid uptake in T2D/obesity; scale-up and supply are critical. Verzenio and Taltz hold high share in growing oncology and IL‑17 markets but need ongoing evidence and geographic expansion. Jardiance remains a durable Star with ~$10B global sales in 2024, driving SGLT2 class growth.
| Product | 2024 signal |
|---|---|
| Mounjaro | Runaway demand, supply focus |
| Zepbound | FDA 11/8/2023; rapid uptake |
| Verzenio | Guideline/adjuvant traction |
| Taltz | Leading share, double‑digit class growth |
| Jardiance | ~$10B sales |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Eli Lilly's portfolio, highlighting Stars, Cash Cows, Question Marks, and Dogs with investment guidance.
Customizable Excel Spreadsheet
One-page Eli Lilly BCG Matrix exposing portfolio pain points with clear actions for faster strategic fixes.
Cash Cows
Trulicity (dulaglutide)
Trulicity (dulaglutide) remains a cash cow for Eli Lilly with 2024 global sales around $6.6 billion, reflecting a large installed base and strong brand recognition. Growth has slowed as prescribers migrate to next‑gen incretins, but it still throws off meaningful cash and supports margins. Minimal promotion beyond retention and access is required; milk while carefully managing formulary erosion and lifecycle defense.
Humalog/Humulin — legacy insulins
Humalog/Humulin are mature, price‑pressured legacy insulins but deliver reliable volume supported by global diabetes prevalence (IDF >537 million adults, 2021) and remain stable cash contributors with limited upside. The Medicare Part D insulin cap of $35/month (effective 2023) sustains pricing pressure into 2024. Operational efficiency—manufacturing optimization and noise minimization—drives margin improvement more than promotion.
Basaglar/Rezvoglar (insulin glargine)
Basaglar and Rezvoglar anchor Lilly’s insulin glargine biosimilar presence in a mature, low-growth basal insulin basin, delivering predictable, payer-driven volumes tied to formulary placement.
Lean manufacturing and tight SG&A control convert steady unit demand into cash generation rather than growth spend.
Priority: defend formulary wins, optimize rebate economics, and let the product run as a margin-preserving cash cow.
Olumiant (baricitinib)
Olumiant (baricitinib) sits as a cash cow for Eli Lilly with mixed indications across rheumatoid arthritis and dermatology, supporting a stable base in a mature JAK inhibitor class; 2024 net sales reported around $3.4 billion, reflecting limited growth but steady recurring revenue and low incremental investment needs, so Lilly appears to be harvesting while monitoring class dynamics and regulatory/competitive shifts.
- Mixed indications: RA, dermatology
- 2024 sales: ≈ $3.4B
- Low incremental CAPEX; stable cash flow
- Strategy: harvest; monitor class/regs
Emgality (galcanezumab) — Migraine
Emgality (galcanezumab) remains a well-known migraine CGRP monoclonal antibody with steady refill dynamics in a crowded field; market growth began moderating by 2024 but Emgality’s share has stayed reasonably durable. Promotion can be targeted rather than broad, supporting high unit margins and disciplined commercial spend, making it a classic Eli Lilly cash cow.
- Approved 2018
- Competes vs Aimovig, Ajovy, Vyepti
- Steady refills, moderated market growth (2024)
- Focused promotion, strong margin profile
Protect formularies, optimize rebates, defend $6.6B and $3.4B cash cows and insulin revenue
Trulicity ($6.6B 2024) and Olumiant ($3.4B 2024) are primary cash cows, yielding steady margins despite slowed growth. Legacy insulins (Humalog/Humulin) and Basaglar/Rezvoglar provide predictable volumes under pricing pressure. Emgality sustains refill revenue with targeted promotion. Focus: defend formularies, optimize rebates, minimize incremental investment.
| Product | 2024 sales | Role | Notes |
|---|---|---|---|
| Trulicity | $6.6B | Cash cow | Installed base, retention focus |
| Olumiant | $3.4B | Cash cow | Stable RA/derm revenue |
| Insulins | — | Cash cow | Volume, price pressure |
| Emgality | — | Cash cow | Durable refills |
What You’re Viewing Is Included
Eli Lilly BCG Matrix
The file you're previewing is the final Eli Lilly BCG Matrix you'll receive after purchase—no watermarks, no placeholders. This exact, professionally formatted report maps Lilly's portfolios into Stars, Cash Cows, Question Marks, and Dogs, ready for strategy use. Once bought, the full document is yours to download, edit, and present—no surprises, just clean, market-informed analysis. Use it straightaway in planning or investor decks.
See the Bigger Picture
Eli Lilly’s BCG Matrix preview shows which drugs are driving growth and which might be holding you back — a quick lens on Stars, Cash Cows, Question Marks, and Dogs. Want the full picture? Purchase the complete BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word + Excel files to guide investment and portfolio decisions. Get instant clarity and skip the guesswork.
Stars
Mounjaro (tirzepatide) — T2D
Mounjaro (tirzepatide) is a BCG Star: runaway 2024 demand and a fat order book fuel massive share in injectable T2D/weight markets. Clinical and real-world data show up to 1.8–2.0% HbA1c reduction and SURMOUNT-1 weight loss to 22.5%, underpinning sustained uptake. Continued value depends on aggressive supply build-out and global rollout muscle to avoid shortages. Keep feeding it and it prints the next decade.
Zepbound (tirzepatide) — Obesity
Zepbound (tirzepatide) — approved by the FDA for chronic weight management on November 8, 2023 — has driven explosive category-defining demand and cultural momentum, quickly taking high share in a still-accelerating obesity market. Marketing, payer access negotiations, and rapid manufacturing scale-up require heavy ongoing investment to sustain growth and convert market lead into a long-term annuity.
Verzenio (abemaciclib) — HR+/HER2− breast cancer
Verzenio (abemaciclib) has strong guideline presence after FDA adjuvant approval in 2021 based on monarchE, and is endorsed in major guidelines such as NCCN and ESMO for HR+/HER2− high‑risk disease.
It is gaining share within the still‑growing CDK4/6 class versus competitors but requires continued confirmatory evidence and geographic label expansions to defend market position.
Ongoing investment in trials, real‑world evidence generation and global rollout is required to keep uptake and revenue trajectory rising.
Jardiance (empagliflozin) — cardio-renal-metabolic (alliance)
Category leader with broad labels and durable physician habit; alliance Jardiance recorded roughly $10 billion global sales in 2024 and continues double-digit volume growth across HF, CKD and T2D. Market still growing: SGLT2 class expected mid-to-high single-digit CAGR, driven by expanding HF/CKD indications and rising prescriptions. Co-promote economics improve with scale; keep flywheel spinning via outcomes readouts and access wins.
- leader
- ~$10B 2024 sales
- expanding HF/CKD/T2D labels
- co-promote economics scale
- focus on outcomes & access
Taltz (ixekizumab) — Immunology
Taltz (ixekizumab) remains a Star for Eli Lilly with leading share in psoriasis and axial spondyloarthritis and healthy new-start volumes in 2024; IL-17 biologics continue double-digit market growth as biologic penetration rises. Competitive landscape is intense but patient retention is high once responders achieve remission; focus on speed of onset and superior skin clearance sustains differentiation.
- 2024: strong new-start momentum, double-digit class growth
- High market share across psoriasis and axSpA
- Sticky adherence once patients respond
- Key differentiator: rapid onset and skin clearance
GLP-1 leaders fuel demand; oncology/IL-17 champs expand; SGLT2 hits $10B
Mounjaro and Zepbound are Stars: category-defining demand and rapid uptake in T2D/obesity; scale-up and supply are critical. Verzenio and Taltz hold high share in growing oncology and IL‑17 markets but need ongoing evidence and geographic expansion. Jardiance remains a durable Star with ~$10B global sales in 2024, driving SGLT2 class growth.
| Product | 2024 signal |
|---|---|
| Mounjaro | Runaway demand, supply focus |
| Zepbound | FDA 11/8/2023; rapid uptake |
| Verzenio | Guideline/adjuvant traction |
| Taltz | Leading share, double‑digit class growth |
| Jardiance | ~$10B sales |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Eli Lilly's portfolio, highlighting Stars, Cash Cows, Question Marks, and Dogs with investment guidance.
Customizable Excel Spreadsheet
One-page Eli Lilly BCG Matrix exposing portfolio pain points with clear actions for faster strategic fixes.
Cash Cows
Trulicity (dulaglutide)
Trulicity (dulaglutide) remains a cash cow for Eli Lilly with 2024 global sales around $6.6 billion, reflecting a large installed base and strong brand recognition. Growth has slowed as prescribers migrate to next‑gen incretins, but it still throws off meaningful cash and supports margins. Minimal promotion beyond retention and access is required; milk while carefully managing formulary erosion and lifecycle defense.
Humalog/Humulin — legacy insulins
Humalog/Humulin are mature, price‑pressured legacy insulins but deliver reliable volume supported by global diabetes prevalence (IDF >537 million adults, 2021) and remain stable cash contributors with limited upside. The Medicare Part D insulin cap of $35/month (effective 2023) sustains pricing pressure into 2024. Operational efficiency—manufacturing optimization and noise minimization—drives margin improvement more than promotion.
Basaglar/Rezvoglar (insulin glargine)
Basaglar and Rezvoglar anchor Lilly’s insulin glargine biosimilar presence in a mature, low-growth basal insulin basin, delivering predictable, payer-driven volumes tied to formulary placement.
Lean manufacturing and tight SG&A control convert steady unit demand into cash generation rather than growth spend.
Priority: defend formulary wins, optimize rebate economics, and let the product run as a margin-preserving cash cow.
Olumiant (baricitinib)
Olumiant (baricitinib) sits as a cash cow for Eli Lilly with mixed indications across rheumatoid arthritis and dermatology, supporting a stable base in a mature JAK inhibitor class; 2024 net sales reported around $3.4 billion, reflecting limited growth but steady recurring revenue and low incremental investment needs, so Lilly appears to be harvesting while monitoring class dynamics and regulatory/competitive shifts.
- Mixed indications: RA, dermatology
- 2024 sales: ≈ $3.4B
- Low incremental CAPEX; stable cash flow
- Strategy: harvest; monitor class/regs
Emgality (galcanezumab) — Migraine
Emgality (galcanezumab) remains a well-known migraine CGRP monoclonal antibody with steady refill dynamics in a crowded field; market growth began moderating by 2024 but Emgality’s share has stayed reasonably durable. Promotion can be targeted rather than broad, supporting high unit margins and disciplined commercial spend, making it a classic Eli Lilly cash cow.
- Approved 2018
- Competes vs Aimovig, Ajovy, Vyepti
- Steady refills, moderated market growth (2024)
- Focused promotion, strong margin profile
Protect formularies, optimize rebates, defend $6.6B and $3.4B cash cows and insulin revenue
Trulicity ($6.6B 2024) and Olumiant ($3.4B 2024) are primary cash cows, yielding steady margins despite slowed growth. Legacy insulins (Humalog/Humulin) and Basaglar/Rezvoglar provide predictable volumes under pricing pressure. Emgality sustains refill revenue with targeted promotion. Focus: defend formularies, optimize rebates, minimize incremental investment.
| Product | 2024 sales | Role | Notes |
|---|---|---|---|
| Trulicity | $6.6B | Cash cow | Installed base, retention focus |
| Olumiant | $3.4B | Cash cow | Stable RA/derm revenue |
| Insulins | — | Cash cow | Volume, price pressure |
| Emgality | — | Cash cow | Durable refills |
What You’re Viewing Is Included
Eli Lilly BCG Matrix
The file you're previewing is the final Eli Lilly BCG Matrix you'll receive after purchase—no watermarks, no placeholders. This exact, professionally formatted report maps Lilly's portfolios into Stars, Cash Cows, Question Marks, and Dogs, ready for strategy use. Once bought, the full document is yours to download, edit, and present—no surprises, just clean, market-informed analysis. Use it straightaway in planning or investor decks.
Original: $10.00
-65%$10.00
$3.50Description
See the Bigger Picture
Eli Lilly’s BCG Matrix preview shows which drugs are driving growth and which might be holding you back — a quick lens on Stars, Cash Cows, Question Marks, and Dogs. Want the full picture? Purchase the complete BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word + Excel files to guide investment and portfolio decisions. Get instant clarity and skip the guesswork.
Stars
Mounjaro (tirzepatide) — T2D
Mounjaro (tirzepatide) is a BCG Star: runaway 2024 demand and a fat order book fuel massive share in injectable T2D/weight markets. Clinical and real-world data show up to 1.8–2.0% HbA1c reduction and SURMOUNT-1 weight loss to 22.5%, underpinning sustained uptake. Continued value depends on aggressive supply build-out and global rollout muscle to avoid shortages. Keep feeding it and it prints the next decade.
Zepbound (tirzepatide) — Obesity
Zepbound (tirzepatide) — approved by the FDA for chronic weight management on November 8, 2023 — has driven explosive category-defining demand and cultural momentum, quickly taking high share in a still-accelerating obesity market. Marketing, payer access negotiations, and rapid manufacturing scale-up require heavy ongoing investment to sustain growth and convert market lead into a long-term annuity.
Verzenio (abemaciclib) — HR+/HER2− breast cancer
Verzenio (abemaciclib) has strong guideline presence after FDA adjuvant approval in 2021 based on monarchE, and is endorsed in major guidelines such as NCCN and ESMO for HR+/HER2− high‑risk disease.
It is gaining share within the still‑growing CDK4/6 class versus competitors but requires continued confirmatory evidence and geographic label expansions to defend market position.
Ongoing investment in trials, real‑world evidence generation and global rollout is required to keep uptake and revenue trajectory rising.
Jardiance (empagliflozin) — cardio-renal-metabolic (alliance)
Category leader with broad labels and durable physician habit; alliance Jardiance recorded roughly $10 billion global sales in 2024 and continues double-digit volume growth across HF, CKD and T2D. Market still growing: SGLT2 class expected mid-to-high single-digit CAGR, driven by expanding HF/CKD indications and rising prescriptions. Co-promote economics improve with scale; keep flywheel spinning via outcomes readouts and access wins.
- leader
- ~$10B 2024 sales
- expanding HF/CKD/T2D labels
- co-promote economics scale
- focus on outcomes & access
Taltz (ixekizumab) — Immunology
Taltz (ixekizumab) remains a Star for Eli Lilly with leading share in psoriasis and axial spondyloarthritis and healthy new-start volumes in 2024; IL-17 biologics continue double-digit market growth as biologic penetration rises. Competitive landscape is intense but patient retention is high once responders achieve remission; focus on speed of onset and superior skin clearance sustains differentiation.
- 2024: strong new-start momentum, double-digit class growth
- High market share across psoriasis and axSpA
- Sticky adherence once patients respond
- Key differentiator: rapid onset and skin clearance
GLP-1 leaders fuel demand; oncology/IL-17 champs expand; SGLT2 hits $10B
Mounjaro and Zepbound are Stars: category-defining demand and rapid uptake in T2D/obesity; scale-up and supply are critical. Verzenio and Taltz hold high share in growing oncology and IL‑17 markets but need ongoing evidence and geographic expansion. Jardiance remains a durable Star with ~$10B global sales in 2024, driving SGLT2 class growth.
| Product | 2024 signal |
|---|---|
| Mounjaro | Runaway demand, supply focus |
| Zepbound | FDA 11/8/2023; rapid uptake |
| Verzenio | Guideline/adjuvant traction |
| Taltz | Leading share, double‑digit class growth |
| Jardiance | ~$10B sales |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Eli Lilly's portfolio, highlighting Stars, Cash Cows, Question Marks, and Dogs with investment guidance.
Customizable Excel Spreadsheet
One-page Eli Lilly BCG Matrix exposing portfolio pain points with clear actions for faster strategic fixes.
Cash Cows
Trulicity (dulaglutide)
Trulicity (dulaglutide) remains a cash cow for Eli Lilly with 2024 global sales around $6.6 billion, reflecting a large installed base and strong brand recognition. Growth has slowed as prescribers migrate to next‑gen incretins, but it still throws off meaningful cash and supports margins. Minimal promotion beyond retention and access is required; milk while carefully managing formulary erosion and lifecycle defense.
Humalog/Humulin — legacy insulins
Humalog/Humulin are mature, price‑pressured legacy insulins but deliver reliable volume supported by global diabetes prevalence (IDF >537 million adults, 2021) and remain stable cash contributors with limited upside. The Medicare Part D insulin cap of $35/month (effective 2023) sustains pricing pressure into 2024. Operational efficiency—manufacturing optimization and noise minimization—drives margin improvement more than promotion.
Basaglar/Rezvoglar (insulin glargine)
Basaglar and Rezvoglar anchor Lilly’s insulin glargine biosimilar presence in a mature, low-growth basal insulin basin, delivering predictable, payer-driven volumes tied to formulary placement.
Lean manufacturing and tight SG&A control convert steady unit demand into cash generation rather than growth spend.
Priority: defend formulary wins, optimize rebate economics, and let the product run as a margin-preserving cash cow.
Olumiant (baricitinib)
Olumiant (baricitinib) sits as a cash cow for Eli Lilly with mixed indications across rheumatoid arthritis and dermatology, supporting a stable base in a mature JAK inhibitor class; 2024 net sales reported around $3.4 billion, reflecting limited growth but steady recurring revenue and low incremental investment needs, so Lilly appears to be harvesting while monitoring class dynamics and regulatory/competitive shifts.
- Mixed indications: RA, dermatology
- 2024 sales: ≈ $3.4B
- Low incremental CAPEX; stable cash flow
- Strategy: harvest; monitor class/regs
Emgality (galcanezumab) — Migraine
Emgality (galcanezumab) remains a well-known migraine CGRP monoclonal antibody with steady refill dynamics in a crowded field; market growth began moderating by 2024 but Emgality’s share has stayed reasonably durable. Promotion can be targeted rather than broad, supporting high unit margins and disciplined commercial spend, making it a classic Eli Lilly cash cow.
- Approved 2018
- Competes vs Aimovig, Ajovy, Vyepti
- Steady refills, moderated market growth (2024)
- Focused promotion, strong margin profile
Protect formularies, optimize rebates, defend $6.6B and $3.4B cash cows and insulin revenue
Trulicity ($6.6B 2024) and Olumiant ($3.4B 2024) are primary cash cows, yielding steady margins despite slowed growth. Legacy insulins (Humalog/Humulin) and Basaglar/Rezvoglar provide predictable volumes under pricing pressure. Emgality sustains refill revenue with targeted promotion. Focus: defend formularies, optimize rebates, minimize incremental investment.
| Product | 2024 sales | Role | Notes |
|---|---|---|---|
| Trulicity | $6.6B | Cash cow | Installed base, retention focus |
| Olumiant | $3.4B | Cash cow | Stable RA/derm revenue |
| Insulins | — | Cash cow | Volume, price pressure |
| Emgality | — | Cash cow | Durable refills |
What You’re Viewing Is Included
Eli Lilly BCG Matrix
The file you're previewing is the final Eli Lilly BCG Matrix you'll receive after purchase—no watermarks, no placeholders. This exact, professionally formatted report maps Lilly's portfolios into Stars, Cash Cows, Question Marks, and Dogs, ready for strategy use. Once bought, the full document is yours to download, edit, and present—no surprises, just clean, market-informed analysis. Use it straightaway in planning or investor decks.
